Idiopathic pulmonary fibrosis (an update ... Huang S, Doyle TJ, Hammer MM, et al. Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: prevalence ...

Opens in a new tab or window Type 2 diabetes (T2D) appeared to double the risk of interstitial lung disease (ILD) in patients with rheumatoid ... in idiopathic pulmonary fibrosis (IPF), according ...

The conditions commonly considered as ILDs include various disorders such as idiopathic pulmonary fibrosis (IPF), connective tissue ... and ILDs (e.g., Rheumatoid arthritis, Scleroderma, Sjogren ...

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid ... including idiopathic pulmonary fibrosis (IPF) therapy ziritaxestat ...

Diabetes Increases ILD Risk in Patients With RA Type 2 diabetes (T2D) appeared to double the risk of interstitial lung ...

Galapagos is in the roll-out phase for its first commercial products – JAK1 inhibitor Jyseleca (filgotinib) for rheumatoid ... including idiopathic pulmonary fibrosis (IPF) candidate ...

Agomab is developing therapies that modulate fibrosis and promote regeneration in chronic conditions such as fibrostenosing ...

as well as the relationship between the extent of traction bronchiectasis and exacerbations in idiopathic pulmonary fibrosis (IPF). The overarching message from the symposium was that advances are ...

Particularly, a research - examined lung biopsies from RA-ILD patients, supported that pathogenic fibroblasts overexpress IL-17A receptor (IL-17RA), in contrast to cells from either normal or ...

Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function, worsening quality of life, and high mortality. However, the rate and pattern of progression of IPF ...